FDA Grants Accelerated Approval to Tudriqev for Anti-PD-1 Refractory Advanced Melanoma

The accelerated approval of Tudriqev (vusolimogene oderparepvec-wtpg) by the FDA on August 6, 2026, places a genetically modified oncolytic viral therapy into commercial manufacturing for the first time under CBER oversight, carrying with it a set of CMC obligations that biologics manufacturers and QA leads should map against existing comparability and potency frameworks now.

Tudriqev is an engineered herpes simplex virus type 1 (HSV-1) indicated in combination with nivolumab for adult patients with unresectable advanced cutaneous melanoma who progressed on a PD-1-blocking regimen. The clinical basis for approval rests on a 140-patient, open-label, single-arm trial in which 24% of 91 evaluable patients achieved an objective response, with a median response duration of 14.1 months. Accelerated approval means a confirmatory trial is required; CBER's post-market expectations will define the evidentiary bar manufacturers must sustain.

For manufacturing and regulatory leads, the product's mechanism introduces compounding complexity. Tudriqev is administered by direct intratumoral injection on a dose-escalation schedule: a lower concentration for the first dose, followed by a higher concentration across seven subsequent doses every two weeks, with volume titrated to tumor size. That variable dosing architecture demands robust potency assays and lot-release specifications capable of distinguishing concentration tiers, a comparability challenge that intensifies at commercial scale under 21 CFR Part 600 and ICH Q5A expectations for viral biologics.

The HSV-1 backbone also introduces a biosafety dimension with direct GMP implications. Labeled safety warnings include risk of herpes transmission to close contacts and potential viral reactivation in patients, signals that will inform containment protocols, personnel exposure controls, and environmental monitoring programs at manufacturing sites handling live viral product. Facilities not currently licensed for HSV-derived biologics should assess their current GMP infrastructure against CBER's existing guidance on viral vector manufacturing before any technology transfer or contract manufacturing discussions proceed.

On July 30, 2026, FDA convened the Cellular, Tissue, and Gene Therapies Advisory Committee to review the data package, indicating the agency applied its full advisory apparatus before granting approval, a signal that CBER will scrutinize post-approval CMC supplements and comparability protocols with corresponding rigor.

The confirmatory trial requirement embedded in the accelerated approval pathway sets a measurable near-term checkpoint: the sponsor must demonstrate clinical benefit in a randomized, controlled setting, and any manufacturing changes introduced between now and that readout will require comparability data sufficient to bridge the commercial product to the approved clinical material.

Source: U.S. Food and Drug Administration via FDA.gov press announcements, August 6, 2026. FDA Cellular, Tissue, and Gene Therapies Advisory Committee convened July 30, 2026.